Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.58 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.
Analysts expect Signet Jewelers Limited (NYSE:SIG) to report $4.04 EPS on March, 8.They anticipate $0.01 EPS change or 0.25% from last quarter’s $4.03 EPS. SIG’s profit would be $244.46M giving it 3.18 P/E if the $4.04 EPS is correct. After having $0.15 EPS previously, Signet Jewelers Limited’s analysts see 2,593.33% EPS growth. The stock increased 0.18% or $0.09 during the last trading session, reaching $51.33. About 1.62M shares traded. Signet Jewelers Limited (NYSE:SIG) has declined 46.03% since February 17, 2017 and is downtrending. It has underperformed by 62.73% the S&P500.
Among 21 analysts covering Signet Jewelers (NYSE:SIG), 8 have Buy rating, 0 Sell and 13 Hold. Therefore 38% are positive. Signet Jewelers had 71 analyst reports since July 28, 2015 according to SRatingsIntel. As per Thursday, October 29, the company rating was upgraded by Goldman Sachs. JP Morgan downgraded the shares of SIG in report on Tuesday, August 30 to “Neutral” rating. The firm has “Market Perform” rating by Cowen & Co given on Tuesday, September 13. The firm has “Buy” rating by Deutsche Bank given on Tuesday, August 23. On Wednesday, February 3 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Tuesday, November 21 the stock rating was downgraded by Wells Fargo to “Hold”. The firm has “Hold” rating by Susquehanna given on Wednesday, January 10. The rating was maintained by Cowen & Co on Tuesday, September 12 with “Hold”. The firm has “Neutral” rating by CL King given on Friday, May 26. Susquehanna initiated it with “Hold” rating and $60.0 target in Thursday, November 2 report.
Investors sentiment decreased to 0.77 in 2017 Q3. Its down 0.20, from 0.97 in 2017Q2. It dived, as 32 investors sold Signet Jewelers Limited shares while 132 reduced holdings. 61 funds opened positions while 66 raised stakes. 67.66 million shares or 6.80% less from 72.59 million shares in 2017Q2 were reported. Cibc accumulated 0.01% or 9,399 shares. 11,285 are held by Campbell And Invest Adviser Ltd Limited Liability Company. South Dakota Council holds 0.05% in Signet Jewelers Limited (NYSE:SIG) or 35,400 shares. Ngam Advsrs Ltd Partnership holds 0.02% or 32,463 shares in its portfolio. Bnp Paribas Arbitrage Sa has 0.02% invested in Signet Jewelers Limited (NYSE:SIG). Caisse De Depot Et Placement Du Quebec reported 13,091 shares. Ameritas Inv Partners Incorporated owns 1,657 shares. Andra Ap stated it has 0.04% in Signet Jewelers Limited (NYSE:SIG). Panagora Asset Mngmt reported 0% of its portfolio in Signet Jewelers Limited (NYSE:SIG). Moore Cap Management Limited Partnership holds 0.03% of its portfolio in Signet Jewelers Limited (NYSE:SIG) for 21,764 shares. Omers Administration, a Ontario – Canada-based fund reported 29,200 shares. Ww Asset Inc reported 0.01% in Signet Jewelers Limited (NYSE:SIG). Tocqueville Asset Management L P holds 7,312 shares or 0.01% of its portfolio. Fifth Third State Bank invested in 0% or 3,009 shares. Corvex Mngmt Lp reported 335,052 shares or 0.84% of all its holdings.
Signet Jewelers Limited engages in the retail sale of diamond jewelry, watches, and other products in the United States, Canada, Puerto Rico, the United Kingdom, the Republic of Ireland, and the Channel Islands. The company has market cap of $3.11 billion. The Company’s Sterling Jewelers division operates stores in malls and off-mall locations primarily under the Kay Jewelers, Kay Jewelers Outlet, Jared The Galleria Of Jewelry, Jared Vault, and various mall regional brands. It has a 7.8 P/E ratio. As of January 28, 2017, this division operated 1,588 stores.
Since January 11, 2018, it had 1 insider buy, and 0 sales for $5.00 million activity. Edelman Oded bought $5.00 million worth of stock or 90,398 shares.
Cormorant Asset Management Llc holds 5.74% of its portfolio in Theravance Biopharma, Inc. for 950,000 shares. Foundation Asset Management Lp owns 432,532 shares or 4.61% of their US portfolio. Moreover, Baupost Group Llc Ma has 3.97% invested in the company for 9.31 million shares. The Massachusetts-based Opaleye Management Inc. has invested 2.18% in the stock. Old West Investment Management Llc, a California-based fund reported 113,942 shares.
Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 earnings per share, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual earnings per share reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.
The stock decreased 1.18% or $0.35 during the last trading session, reaching $29.26. About 86,699 shares traded. Theravance Biopharma, Inc. (TBPH) has risen 89.85% since February 17, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.